Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia

J Am Acad Dermatol. 2013 Nov;69(5):839-840. doi: 10.1016/j.jaad.2013.07.025.

¹ Department of Dermatology, Referral Centre for Auto-immune and Toxic Bullous Diseases, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.
² Laboratory of Hematology, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.
³ Department of Pathology, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.
⁴ Department of Hematology, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.
⁵ Laboratory of Pharmacology, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.
⁶ Department of Dermatology, Referral Centre for Auto-immune and Toxic Bullous Diseases, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France; INSERM, CIC 006, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.
⁷ Department of Dermatology, Referral Centre for Auto-immune and Toxic Bullous Diseases, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France; LIC EA4393, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France. Electronic address: laurence.allanore@hmn.ap-hp.fr.

No abstract available

Publication types